Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
Rhea-AI Summary
Nuwellis (Nasdaq: NUWE) will report Q4 and full-year 2025 financial results on March 10, 2026. A conference call and webcast are scheduled for 9:00 AM ET to discuss results and provide a business update.
According to Nuwellis, the live webcast and an audio archive will be available on the company Investors page, and dial-in details and conference ID NUWEQ4 are provided for listeners.
Positive
- None.
Negative
- None.
News Market Reaction – NUWE
On the day this news was published, NUWE declined 4.73%, reflecting a moderate negative market reaction. Argus tracked a peak move of +6.8% during that session. This price movement removed approximately $160K from the company's valuation, bringing the market cap to $3M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: BBLG -2.5%, VTAK -4.19%, NAOV -1.95%, TIVC -10.13%, VERO +2.94%. With only one momentum peer (BJDX -2.58%) and NUWE down 8.65%, trading appears more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 30 | CFO appointment | Positive | -10.0% | New Chief Financial Officer hired to support next phase of growth. |
| Jan 29 | Financing transaction | Negative | +8.6% | Priced-at-the-market private placement and warrant inducement for $5M gross. |
| Jan 29 | Strategic acquisition | Positive | +8.6% | Agreement to acquire Rendiatech and expand kidney monitoring offerings. |
| Jan 23 | Board changes | Neutral | -3.1% | Multiple director resignations and appointments with governance experience. |
| Jan 06 | Patent issuance | Positive | +4.6% | New U.S. patent for pediatric extracorporeal therapy safety mechanisms. |
Recent corporate and financing news has produced mixed reactions, with some strategic and financing updates selling off despite seemingly positive or neutral content.
Over recent months, Nuwellis has focused on recapitalizing and repositioning its business. A January private placement and warrant inducement raised about $5.0M and coincided with an acquisition agreement for Rendiatech to expand its cardiorenal portfolio. Board refresh and a new CFO appointment marked governance and leadership changes. A new U.S. patent supported pediatric extracorporeal therapy innovation. Reactions have been uneven, with both declines (e.g., CFO appointment at -10.02%) and gains (financing/acquisition at +8.55%), framing a volatile backdrop heading into the 2025 earnings release date.
Regulatory & Risk Context
An effective S-3 resale registration filed on 2026-02-03 covers up to 4,279,325 warrant-related shares. Nuwellis is not selling shares directly but may receive up to $28 million if all registered warrants are exercised for cash, which could increase the share count beyond the 1,873,892 shares outstanding as of January 31, 2026.
Market Pulse Summary
This announcement sets the timetable for Nuwellis’ Q4 and full-year 2025 results on March 10, 2026, following a period of financing, acquisition activity, and governance changes. Investors may focus on Q4 revenue trends versus the Q3 2025 net sales of $2.217M, cash levels after prior offerings, and any updates to going-concern language. Warrant-related registrations covering 4,279,325 shares and the potential for up to $28M in warrant exercise proceeds remain important context for dilution and balance sheet evolution.
AI-generated analysis. Not financial advice.
MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update.
To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com.
Alternatively, you may access the live conference call by dialing 1-800-343-4885 (U.S) or 1-203-518-9851 (international) and using the conference ID: NUWEQ4. An audio archive of the webcast will be available following the call on the Investors page at https://ir.nuwellis.com.
About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company advancing precision fluid management technologies across the cardiorenal continuum. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations.
About the Aquadex SmartFlow® System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
ir@nuwellis.com
Media Contact:
Leah McMullen
Director of Communications
Leah.mcmullen@nuwellis.com
FAQ
When will Nuwellis (NUWE) report Q4 and full-year 2025 financial results?
How can investors listen to the Nuwellis (NUWE) March 10, 2026 earnings call?
Will Nuwellis (NUWE) provide a replay of the March 10, 2026 webcast?
What time is the Nuwellis (NUWE) conference call on March 10, 2026 and what is the conference ID?
Where can I find dial-in numbers for the Nuwellis (NUWE) earnings call on March 10, 2026?
